Diazyme Laboratories Introduces New Test for the Early Detection of Kidney Disease
2/26/2008 9:40:58 AM
POWAY, CA--(Marketwire - February 25, 2008) - Diazyme Laboratories announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(k) clearance to market its Cystatin C Assay Kit for the quantitative determination of Cystatin C in serum and plasma samples. Cystatin C is emerging as a biomarker superior to standard tests of kidney function in the early detection of chronic kidney disease. There is a growing body of evidence that indicates that some of the negative outcomes of chronic kidney disease can be averted with early diagnosis and treatment.
comments powered by